While Q3 2019 M&A activity remains short of prior year in Life Sciences and Chemicals, large deals continue to dominate the M&A landscape. Life Sciences` deal value continues to outpace prior year including blockbuster deals, portfolio reorganization, oncology and medical cannabis deals. M&A within Chemicals shows a similar picture, yet at a lower level, primarily driven by structural changes in China and large acquisitions in the US.